3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
73
Neoplasm Metastasis
30
Kidney Neoplasms
26
Neoplasms
19
Breast Neoplasms
14
Prostatic Neoplasms
12
Urinary Bladder Neoplasms
10
Melanoma
9
Gastrointestinal Stromal Tumors
9
Brain Neoplasms
9
Glioblastoma
8
Sarcoma
7
Carcinoma, Non-Small-Cell Lung
7
Liver Neoplasms
6
Carcinoma, Hepatocellular
6
Recurrence
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Esophageal Neoplasms
5
Colorectal Neoplasms
5
Thyroid Neoplasms
4
Solid Tumors
4
Osteosarcoma
4
Lung Neoplasms
4
Leukemia, Myeloid, Acute
4
Adenocarcinoma
4
Uveal Melanoma
3
Thymoma
3
Stomach Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Interventions
parathyroid hormone-related peptide (1-36)
2
Musculoskeletal Manipulations
2
Cisplatin
2
niraparib
1
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
anlotinib
1
adrenosterone
1
Ultrasonography
1
Thalidomide
1
Sunitinib
1
Parathyroid Hormone-Related Protein
1
Parathyroid Hormone
1
Paclitaxel
1
Octreotide
1
Melphalan
1
Lutetium-177
1
Lutetium
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Hematologic Tests
1
Gemcitabine
1
Filgrastim
1
Etoposide
1
Eating
1
Doxorubicin
1
Diffusion
1
Dexamethasone
1
Dehydroepiandrosterone
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Endocrine System Diseases
×
Sunitinib
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled